• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Kodiak Sciences Inc (Amendment)

    2/14/23 4:19:55 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KOD alert in real time by email
    SC 13G/A 1 d432730dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

     

    Kodiak Sciences Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    50015M109

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-l(b)

    ☐ Rule 13d-l(c)

    ☒ Rule 13d-l(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


      SCHEDULE 13G  
    CUSIP No. 50015M109     Page 2 of 5 Pages

     

      1.    

      Names of Reporting Persons.

     

      D. Victor Perlroth, M.D.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      United States of America

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.     

      Sole Voting Power

     

      6,691,321 shares1

       6.   

      Shared Voting Power

     

      N/A

       7.   

      Sole Dispositive Power

     

      6,164,321 shares2

       8.   

      Shared Dispositive Power

     

      N/A

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      6,691,321

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      12.2%3

    12.  

      Type of Reporting Person (See Instructions)

     

      IN

     

     

     

    1 

    Includes (a) 3,448,038 shares held directly by Dr. Perlroth, (b) 2,656,283 shares of common stock that Dr. Perlroth has the right to acquire from the Issuer immediately or within sixty days of December 31, 2022 pursuant to the exercise of option awards, of which 549,876 are unvested, early exercisable and subject to an Issuer right of repurchase as of March 1, 2023; (c) 60,000 shares held by the Perlroth Family Foundation U/A DTD 12/27/2006 for which Dr. Perlroth is a trustee, and (d) 527,000 shares as to which Dr. Perlroth exercises sole voting authority pursuant to a voting agreement and proxy.

    2 

    Includes (a) 3,448,038 shares held directly by Dr. Perlroth, (b) 2,656,283 shares of common stock that Dr. Perlroth has the right to acquire from the Issuer immediately or within sixty days of December 31, 2022 pursuant to the exercise of option awards, of which 549,876 are unvested, early exercisable and subject to an Issuer right of repurchase as of March 1, 2023, and (c) 60,000 shares held by the Perlroth Family Foundation U/A DTD 12/27/2006 for which Dr. Perlroth is a trustee.

    3 

    Based on 52,333,850 shares of common stock outstanding as of December 31, 2022.


      SCHEDULE 13G  
    CUSIP No. 50015M109     Page 3 of 5 Pages

     

    Item 1.

     

      (a)

    Name of Issuer:

    Kodiak Sciences Inc. (the “Issuer”)

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    1200 Page Mill Road

    Palo Alto, CA 94304

    Item 2.

     

      (a)

    Name of Person Filing:

    D. Victor Perlroth, M.D.

     

      (b)

    Address of Principal Business Office or, if none, Residence:

    The address for the Reporting Person is:

    c/o Kodiak Sciences Inc.

    1200 Page Mill Road

    Palo Alto, CA 94304

     

      (c)

    Citizenship:

    Dr. D. Victor Perlroth is a United States citizen.

     

      (d)

    Title of Class of Securities:

    Common Stock, $0.0001 par value per share

     

      (e)

    CUSIP Number:

    50015M109

    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)    ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)    ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)    ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)    ☐ An investment advisor in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)    ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)    ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
    (h)    ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)    ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); or
    (k)    ☐ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).


      SCHEDULE 13G  
    CUSIP No. 50015M109     Page 4 of 5 Pages

     

    Item 4. Ownership.

    The following information with respect to the ownership of the Common Stock of the Issuer by the Reporting Person is provided as of December 31, 2022:

     

      (a)

    Amount beneficially owned

    See Row 9 of cover page.

     

      (b)

    Percent of Class:

    See Row 11 of cover page.

     

      (c)

    Number of shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote    See Row 5 of cover page.
    (ii) Shared power to vote or to direct the vote    See Row 6 of cover page.
    (iii) Sole power to dispose or to direct the disposition of    See Row 7 of cover page.
    (iv) Shared power to dispose or to direct the disposition of    See Row 8 of cover page.

    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.

    Item 8. Identification and Classification of Members of the Group.

    Not applicable.

    Item 9. Notice of Dissolution of Group.

    Not applicable.

    Item 10. Certifications.

    Not applicable.


      SCHEDULE 13G  
    CUSIP No. 50015M109     Page 5 of 5 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

          D. Victor Perlroth, M.D.
    Date: February 14, 2023       /s/ D. Victor Perlroth
    Get the next $KOD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KOD

    DatePrice TargetRatingAnalyst
    8/14/2025$15.00Underweight → Neutral
    Analyst
    12/9/2024$20.00Hold → Buy
    Jefferies
    9/5/2024$3.00Neutral
    H.C. Wainwright
    12/11/2023$2.00Sell
    Goldman
    11/17/2023$7.00 → $12.00Equal Weight → Overweight
    CapitalOne
    7/27/2023$15.00 → $4.00Buy → Neutral
    UBS
    7/25/2023Buy → Neutral
    Chardan Capital Markets
    7/25/2023Neutral → Underweight
    JP Morgan
    More analyst ratings

    $KOD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Kodiak Sciences upgraded by Analyst with a new price target

    Analyst upgraded Kodiak Sciences from Underweight to Neutral and set a new price target of $15.00

    8/14/25 8:06:05 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kodiak Sciences upgraded by Jefferies with a new price target

    Jefferies upgraded Kodiak Sciences from Hold to Buy and set a new price target of $20.00

    12/9/24 7:57:06 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Kodiak Sciences with a new price target

    H.C. Wainwright initiated coverage of Kodiak Sciences with a rating of Neutral and set a new price target of $3.00

    9/5/24 7:49:18 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results

    PALO ALTO, Calif., Aug. 13, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2025. "Our July 16 Investor R&D Day brought forward compelling new data along with a clear commercial vision for our three late-stage clinical assets –tarcocimab, KSI-501 and KSI-101– underscoring their transformative potential in retinal disease treatment," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "The event featured new 12-week data from the KSI-101 APEX Phase 1b study, underscoring the opportunity for KSI-101 to treat patients with macular edema secondary to inflammation (ME

    8/13/25 4:00:00 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kodiak Sciences to Host Investor R&D Day on July 16, 2025

    PALO ALTO, Calif.  , July 10, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina focused biotechnology company committed to researching, developing, and commercializing transformative therapeutics, announced today it will host an investor R&D Day webcast on Wednesday, July 16, 2025, from 4:00 pm ET to 5:30 pm ET. The virtual event will feature a comprehensive overview of Kodiak's three late-phase clinical assets (tarcocimab, KSI-501, KSI-101) through presentations from members of Kodiak's senior leadership team complemented by distinguished industry experts. A live webcast of this event will be available to investors and other interested parties. Registration for

    7/10/25 8:00:00 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society

    PALO ALTO, Calif., June 25, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management along with key opinion leaders will present KSI-101 highlights at the 2025 Congress of the International Ocular Inflammation Society (IOIS) in Rio de Janeiro, Brazil on Friday, June 27, 2025. "We are excited to participate in this year's IOIS meeting and connect with leading experts in ocular inflammation to help advance care for patients with macular edema caused by inflammation," said Pablo Velazquez-Martin, MD, Chief

    6/25/25 4:45:00 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Officer Borgeson John A.

    4 - Kodiak Sciences Inc. (0001468748) (Issuer)

    7/8/25 4:33:23 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chairman and CEO Perlroth Victor

    4 - Kodiak Sciences Inc. (0001468748) (Issuer)

    7/8/25 4:30:46 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Baker Bros. Advisors Lp

    4 - Kodiak Sciences Inc. (0001468748) (Issuer)

    7/2/25 5:08:03 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOD
    SEC Filings

    View All

    SEC Form 10-Q filed by Kodiak Sciences Inc

    10-Q - Kodiak Sciences Inc. (0001468748) (Filer)

    8/13/25 4:11:10 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kodiak Sciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Kodiak Sciences Inc. (0001468748) (Filer)

    8/13/25 4:00:37 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Kodiak Sciences Inc

    8-K - Kodiak Sciences Inc. (0001468748) (Filer)

    6/3/25 4:29:59 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOD
    Leadership Updates

    Live Leadership Updates

    View All

    Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

    PALO ALTO, Calif., Sept. 17, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that it will host an Investor R&D Day with financial analysts and institutional investors on Monday, September 23, 2024, in New York City from 10:30 am ET to 12:30 pm ET. The event will feature presentations and roundtable discussions on Kodiak's science of durability, science of the enhanced formulation, timeline and other updates for the Company's active clinical pipeline, and the Company's expanding Antibody Biopolymer Conjugate Dr

    9/17/24 4:05:00 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pipeline Therapeutics Appoints Julie Iwashita as Vice President of Clinical Operations

    SAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Julie Iwashita as the company’s Vice President of Clinical Operations. Ms. Iwashita brings more than 30 years of experience guiding global neurology and other clinical development programs through the U.S. Food and Drug Administration (FDA) and other global health authorities. “I am delighted to welcome Julie to Pipeline Therapeutics to spearhead our clinical development efforts,” said Carmine Stengone, President & CEO of Pipeline Therapeutics. “Julie’s extensive

    12/3/20 11:00:00 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOD
    Financials

    Live finance-specific insights

    View All

    Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

    PALO ALTO, Calif., March 26, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that it will report fourth quarter and full-year 2023 financial results on Thursday, March 28, 2024. Management will host a conference call and live webcast to discuss recent business highlights and provide a corporate update at 4:30 p.m. Eastern Time on March 28, 2024. To access the webcast, please register at https://edge.media-server.com/mmc/p/q4jdxku4/. A live audio webcast of the event will be available on the "Events and Presentatio

    3/26/24 6:15:00 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

    PALO ALTO, Calif., Feb. 23, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD) today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3 clinical trial evaluating the efficacy, durability and safety of KSI-301, a novel antibody biopolymer conjugate, in treatment-naïve subjects with neovascular (wet) age-related macular degeneration. The trial randomized 559 participants, approximately 80% of whom were enrolled in the United States. The study had two treatment arms: KSI-301 5mg on a flexible long-interval regimen and aflibercept 2mg on a fixed short-interval regimen. In the study, three monthly loading doses were administered to all subje

    2/23/22 6:00:00 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KOD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Kodiak Sciences Inc (Amendment)

    SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)

    2/14/24 4:23:00 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Kodiak Sciences Inc (Amendment)

    SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)

    1/26/24 11:49:38 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Kodiak Sciences Inc (Amendment)

    SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)

    2/14/23 4:19:55 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care